Livtencity generics — when can they launch?
Livtencity (MARIBAVIR) · Takeda · 7 active US patents · 0 expired
Where Livtencity sits in the generic timeline
Mid-term cliff: earliest active US patent for Livtencity expires in 2031 (~5 years). Generic developers typically begin ANDA bioequivalence studies 3-4 years ahead of this date. Paragraph IV filings + Hatch-Waxman 30-month stays may shift the effective entry by another 18-36 months.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Method of Use — 5 patents
- Composition of Matter — 2 patents
FDA U-codes carved out by Livtencity patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-4329 | (no description) |
U-3650 | (no description) |
U-4137 | (no description) |
U-4328 | (no description) |
U-4289 | (no description) |
Sample patent estate
Showing 6 of 7 active US patents. View full estate on the Livtencity drug page →
-
This patent protects novel compositions and methods of using maribavir to enhance its effectiveness in medical therapy and counteract adverse effects of maribavir isomerization.USPTO title: Maribavir isomers, compositions, methods of making and methods of using
-
This patent protects novel compositions and methods of using maribavir to enhance its effectiveness in medical therapy and counteract adverse effects of maribavir isomerization.USPTO title: Maribavir isomers, compositions, methods of making and methods of using
-
This patent protects a method of using maribavir in treatment regimens.USPTO title: Use of maribavir in treatment regimens
-
This patent protects a method of using maribavir in treatment regimens.USPTO title: Use of maribavir in treatment regimens
-
This patent protects a method of using maribavir in treatment regimens.USPTO title: Use of maribavir in treatment regimens
-
This patent protects the composition of maribavir, a benzimidazole riboside used as an orally available antiviral medication against cytomegalovirus (CMV).USPTO title: Viral inhibitors, the synthesis thereof, and intermediates thereto
Sources
- FDA Orange Book — patents listed against Livtencity (NDA filed 2021)
- Livtencity drug profile — full patent estate, indications, clinical trials, pricing
- Takeda patent portfolio
- Patent cliff 2031 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Livtencity — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →